Hyperlipoproteinemia medical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
==Medical Therapy== | ==Medical Therapy== | ||
* [[Hyperlipidemia NCEP recommendations for drug therapy of high-risk hyperlipidemia in children and adolescents | Recommendations for drug therapy]] | |||
* [[Hyperlipidemia statins in children and adolescents with hyperlipidemia | Statins]] | |||
* [[Hyperlipidemia NCEP guidelines for adjuvant therapies in children and adolescents | Adjuvant therapies]] | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Revision as of 14:50, 24 August 2012
|
Lipoprotein Disorders Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]